(S)-Zanubrutinib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

(S)-Zanubrutinib (BGB3111) 是一种有效的、选择性的、口服的 Btk 抑制剂。

(S)-Zanubrutinib (BGB3111)?is a potent, selective and orally available Btk inhibitor; shows much more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib; demonstrates nanomolar BTK inhibition activity, inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation in several MCL and DLBCL cell lines; demonstrates better anti-tumor activity than ibrutinib in TMD-8 subcutaneous xenograft model.

——

——

S)-Zanubrutinib | BGB3111 | BGB 3111

Tyrosine Kinase

BTK

BTK

Cancer

——

1691249-45-2

471.561

C27H29N5O3

>98% (HPLC)

DMSO : ≥ 56.75 mg/mL 120.35 mM; Ethanol : < 1 mg/mL

C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N

(7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

(-20℃)

With Ice Pack

≥ 2 years